Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)

Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head & Neck Surgery at Stanford University.

Start Date01 Jul 2026

Sponsor / Collaborator

Stanford University

NCT06237062

/ TerminatedNot Applicable

Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

Start Date05 Jun 2024

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT06212661

/ Enrolling by invitationNot ApplicableIIT

Migraine Medication Effects on Urinary Symptoms

A prospective observational cohort trial to study the effects of CGRP inhibitors (CGRPi) on lower urinary tract symptoms (LUTS) and bladder/pelvic pain. Candidates for either CGRPi or an alternative therapy for refractory migraines (OnabotulinumtoxinA (BoNTA) extracranial muscle injections) with baseline LUTS will be recruited. The investigators will assess LUTS and pelvic pain using validated symptom and quality-of-life questionnaires, pretreatment and at 3 months post-treatment follow-up, comparing change in symptoms based on treatment received.

Start Date05 Apr 2024

Sponsor / Collaborator

The Cleveland Clinic Foundation

100 Clinical Results associated with Erenumab (Genetical Recombination)

100 Translational Medicine associated with Erenumab (Genetical Recombination)

100 Patents (Medical) associated with Erenumab (Genetical Recombination)

646

Literatures (Medical) associated with Erenumab (Genetical Recombination)

01 Aug 2026·Pain and Therapy

Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study

Article

Author: Miki, Yasuhiro ; Takizawa, Tsubasa ; Hashimoto, Chie ; Ueda, Kaname ; Takemura, Ryo

INTRODUCTION:

Understanding real-world calcitonin gene-related peptide monoclonal antibodies' (CGRP mAbs) use in patients with migraine is necessary to potentially guide treatment strategies.

METHODS:

This retrospective cohort study analyzed administrative claims data from the IQVIA claims data for Japan. It included CGRP mAb-naïve individuals with confirmed migraine diagnosis and ≥ 1 CGRP mAb prescription (January 2021-June 2023). Index date was the first CGRP mAb prescription. Patient characteristics, treatment patterns, adherence (proportion of days covered ≥ 0.80), persistence, and migraine-related direct costs were assessed. Persistence was measured as the proportion of patients continuing treatment for ≥ 3 or ≥ 6 months (≤ 90-day gap between fills). Factors predicting adherence to CGRP mAb treatment were assessed using multivariate logistic regression. Subgroup analyses were conducted for galcanezumab users.

RESULTS:

Of the 1781 patients included (mean age 41.8 years [standard deviation, SD 10.3]; 79.3% female patients), 55.0% received galcanezumab, followed by fremanezumab (29.7%), and erenumab (15.3%). The prescription rates of concomitant acute and oral preventive medications were 86.1% and 51.3%, respectively, in the first 3 months after initiating CGRP mAb treatment but numerically decreased to 49.8% and 22.5%, respectively, in the fourth to sixth month. The index CGRP mAb persistence rates were 91.9% for ≥ 3 months and 76.9% for ≥ 6 months, and adherence rate was 51.7%. Multiple positive and negative predictors of adherence to CGRP mAbs were observed. Index to 3 months after initiating index CGRP mAbs, the median average monthly migraine-related costs were JPY 75,320 (Q1, Q3 61,593, 89,843) (USD 592), and non-CGRP mAb migraine-related costs were JPY 15,702 (Q1, Q3 8845, 27,848) (USD 123). These costs tended to reduce or plateau for up to 12 months thereafter. The galcanezumab subgroup showed a similar trend.

CONCLUSIONS:

CGRP mAb adherence and ≥ 6 months persistence rates were 51.7% and 76.9%, respectively, in CGRP mAb-initiating adults with migraine in Japan. During CGRP mAb treatment, acute and oral preventive medication prescription rates appeared to reduce, while direct costs initially increased but appeared to reduce from the post-initiation peak and plateau over time, although the underlying reasons could not be determined from claims data.

01 Jul 2026·CEPHALALGIA

Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program

Article

Author: Ong, Bradley ; Thompson, Nicolas ; Gül, Sedat ; Trudeau, Stephen ; Yuan, Hsiangkuo

Aim:

To evaluate whether initiation of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) was non-inferior to initiation of onabotulinumtoxinA with respect to the hazard of ischemic stroke or transient ischemic attack (IS + TIA) in a real-world cohort of adults with migraine.

Methods:

We conducted a retrospective, active-comparator, new-user pharmacoepidemiology study using the NIH All of Us Research Program Registered Tier Dataset (v8). Adults with migraine initiating CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) were compared with initiators of onabotulinumtoxinA from January 2018 through September 2023. The primary outcome was IS + TIA occurring more than 90 days after treatment initiation. Inverse probability of treatment weighting (IPTW) with stabilized propensity scores was used to adjust for 23 baseline covariates. Non-inferiority was assessed on the hazard ratio (HR) scale using a prespecified margin of 1.5, with non-inferiority concluded if the upper bound of the 95% confidence interval (CI) was less than 1.5. Prespecified subgroup analyses included migraine with aura and without aura. Prespecified sensitivity analyses included a per-protocol analysis, a crossover-excluded analysis, and an IS-only analysis. Fracture was used as a negative control outcome.

Results:

Among 16,147 patients with migraine in the cohort, the primary comparison included 1,581 CGRP mAb initiators and 947 onabotulinumtoxinA initiators. IPTW achieved a good covariate balance for the primary comparison (maximum standardized mean difference 0.016). For the primary outcome, 14 IS + TIA events occurred among CGRP mAb initiators and 22 among onabotulinumtoxinA initiators. The hazard ratio for IS + TIA was 0.524 (95% CI 0.263–1.046), which met the prespecified statistical criterion for non-inferiority because the upper confidence bound was below 1.5; however, the estimate was imprecise because of the small number of events. In the migraine with aura subgroup, the estimate also met the non-inferiority criterion (HR 0.419, 95% CI 0.163–1.080), whereas the migraine without aura subgroup, per-protocol analysis, and major adverse cardiovascular events analysis were inconclusive for non-inferiority. For major adverse cardiovascular events the HR was 1.068 (95% CI 0.589–1.935). The fracture negative control was also not significantly different (HR, 1.175; 95% CI, 0.692–1.993; p = 0.551), arguing against systematic healthy-user confounding. A formal adjusted comparison with untreated patients was not feasible due to structural confounding inherent to the stepped-care treatment pathway.

Conclusions:

In this real-world diverse cohort, initiation of CGRP mAbs met the prespecified statistical criterion for non-inferiority relative to onabotulinumtoxinA for the primary IS + TIA outcome. However, this finding was based on few events and wide CIs and should be interpreted cautiously as limited evidence against a large relative increase in incident IS + TIA risk, rather than as definitive evidence of equivalent safety, absence of modest harm, or a protective effect. Several secondary, subgroup, and supportive analyses remained inconclusive for non-inferiority. Larger adequately powered comparative safety studies are needed.

01 Jul 2026·CEPHALALGIA

Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study

Article

Author: Higurashi, Masakazu ; Oshima, Akito ; Ikegaya, Naoki ; Kamogawa, Misaki ; Higurashi, Norimichi

Background:

Evidence supporting calcitonin gene-related peptide monoclonal antibody (CGRP mAb) use in adolescents with migraine is limited. Rapid recovery for daily school functioning is particularly important during this stage of life. We aimed to evaluate early functional outcomes in daily and school activities, as well as headache-related outcomes after initiating CGRP mAb therapy in Japanese adolescents with migraine.

Methods:

This single-center retrospective cohort study included patients aged 15–17 years who received CGRP mAb therapy (galcanezumab, fremanezumab or erenumab) for migraine between May 2021 and July 2025. The primary outcome was time to clinically meaningful improvement on the Headache Impact Test-6 (HIT-6) scores, comprising a reduction of ≥ 6 points from baseline, and was analyzed using the Kaplan–Meier method. Secondary outcomes included tracking longitudinal HIT-6 trajectories with mixed-effects models for repeated measures, exploratory univariable comparisons for early response (≥ 6-point reduction within 10–14 weeks), questionnaire-based daily functioning assessments, and safety evaluations.

Results:

Of 34 adolescents who initiated CGRP mAb therapy, 33 participated in HIT-6 analyses. The cumulative response rate began increasing immediately after treatment initiation, reaching 68.3% (95% confidence interval = 44.6–81.8%) within the 10–14-week period; approximately half of the responders achieved meaningful improvement by weeks 4–6. Mixed-effects models for repeated measures analyses adjusted for baseline HIT-6 scores showed a least-squares mean change of −9.4 points at 12 weeks (95% confidence interval = −14.2 to −4.6; p < 0.001), with benefits sustained over follow-up. Among questionnaire respondents ( n = 27), school attendance or concentration in the classroom was the most affected activity before treatment (70.4%) and 88.9% indicated that their primary treatment goals were mostly or partially achieved. Adverse events were reported by 40.7% of participants, primarily injection-site reactions (29.6%), none of which led to therapy discontinuations or modifications.

Conclusions:

In this real-world adolescent cohort, CGRP mAb therapy was associated with early and clinically meaningful improvements in headache-related impact and self-reported functioning. Safety and tolerability findings are particularly notable given the limited evidence in this age group. Further prospective controlled studies are warranted to validate these findings and to identify predictors of early functional response.

News (Medical) associated with Erenumab (Genetical Recombination)

17 Jun 2026

·firstwordpharma.com

Vedana debuts with $46M and a team of veterans to become 'the migraine company'

While the approval of the first CGRP inhibitor in 2018 was a watershed moment for the migraine disease space, too many patients still have too many migraines, Vedana Therapeutics CEO Anurag Agarwal told FirstWord. The biotech, which launched on Wednesday with $46 million in series A funding, is led by experts who helped usher in the first migraine revolution — but recognise that more work is needed. CGRP inhibitors "were the first specialised treatments designed for migraine patients," Agarwal said. "However, two-thirds of patients don't have sufficient benefits, they don't have deep reductions in migraine days" after trying therapies like Amgen's Aimovig (erenumab-aooe) or Teva's Ajovy (fremanezumab-vfrm). To help non-responders get migraine relief, Vedana is developing antibodies that inhibit a wholly independent pathway involving pituitary adenylate cyclase-activating polypeptide (PACAP). "PACAPs, like CGRPs, have been shown that when you infuse it in migraine patients, it induces migraine-like headaches. But unlike CGRPs, it induced a much broader symptomology of migraine… [like] facial puffing, neck stiffness," Agarwal said. In early studies, even with complete CGRP blockade, the infusion of PACAPs still drove migraines, demonstrating that it is a "complementary pathway that could address what is not being addressed by CGRPs today," he added. The company's two lead programmes are a next-generation anti-PACAP mAb and a dual-targeting PACAP/CGRP bispecific antibody. With Wednesday's funding, co-led by Westlake BioPartners and Canaan Partners, Vedana hopes to move both into the clinic next year.Migraine competitionThe biotech is not alone in its pursuit of PACAP inhibition, however. Lundbeck looks to be the most advanced with bocunebart, a PACAP-targeting mAb that recently met the primary endpoint of a Phase IIb migraine study, though several others, including newly public Mentari Therapeutics and Slate Medicines, have preclinical PACAP assets. Despite the rapidly forming PACAP competition, Agarwal isn't worried, noting that CGRP development was also a crowded field. He also called the early success of Lundbeck's programme "wonderful" for patients. How Vedana will stand out, he said, is with best-in-class treatments that are more potent, long-acting, and can be delivered subcutaneously in a patient's home with an autoinjector. "Our goal is to be able to give medicines that are easily delivered to a large number of patients," Agarwal added.Lending Vedana a hand in meeting that goal is its team of experienced migraine scientists. Leon Garcia, the company's other co-founder and chief scientist, previously led the discovery and development of both anti-CGRP and -PACAP antibodies at Alder BioPharmaceuticals, which was acquired by Lundbeck in 2019 for close to $2 billion. Chief Medical Officer Ernesto Aycardi steered the pivotal and post-marketing studies for Ajovy, and Rob Lenz, executive chairman of the board, helmed Aimovig's development in his past role as Amgen's head of global development. "We have that unique experience of discovering, developing and bringing to patients migraine therapies. We have a team that has done that from the early to the late stages. So I think that we are in a very unique position to lead the field," Aycardi told FirstWord. "This company in the future is going to be the migraine company."

Phase 2AcquisitionDrug ApprovalClinical Result

17 Jun 2026

·allsci.com

Vedana launches with USD 46m via Series A to challenge CGRP monopoly in migraine prevention

Seattle-based Vedana Therapeutics has launched from stealth with a USD 46 million Series A financing round to advance a portfolio of antibody-based therapies targeting clinically validated pathways for migraine prevention. The round was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s pipeline centers on pituitary adenylate cyclase-activating polypeptide (PACAP) biology. Its lead program is a next-generation anti-PACAP antibody, and its second program is a bispecific antibody targeting both PACAP and calcitonin gene-related peptide (CGRP). PACAP is a neuropeptide that, like CGRP, plays a documented role in migraine physiology. Vedana’s antibodies are designed as long-acting, subcutaneously delivered agents intended for self-injection. CGRP-targeted antibodies — including erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) — established the first generation of preventive migraine biologics and represented a meaningful clinical advance. However, the company and its investors contend that approximately two-thirds of patients remain inadequately controlled on existing therapies, creating a substantial opportunity for agents targeting complementary biology such as PACAP. Competitors in the emerging PACAP space include Lundbeck, which acquired Alder BioPharmaceuticals — the company where Vedana’s co-founder and chief scientific officer Leon Garcia, Ph.D., previously led anti-CGRP and anti-PACAP antibody discovery — and AbbVie, which has disclosed PACAP-targeting programs. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

AcquisitionIPOGene Therapy

17 Jun 2026

·www.biospace.com

Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies

Targeting clinically validated pathways to enable patients to achieve freedom from migraine Built by the world’s foremost migraine experts and industry leaders Financing co-led by Westlake BioPartners and Canaan Partners SEATTLE--(BUSINESS WIRE)--Vedana Therapeutics (“Vedana”), a biotechnology company developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. The financing was co-led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma and Alexandria Venture Investments. Vedana’s executive team, board, and advisors include leaders who discovered and developed multiple migraine therapies, including approved calcitonin gene-related peptide (CGRP) antibodies and the emerging pituitary adenylate cyclase-activating polypeptide (PACAP) drug class. Proceeds from the financing will be used to advance Vedana’s portfolio of internally discovered, potentially best-in-class, subcutaneously delivered antibodies targeting clinically validated pathways for migraine prevention. “First-generation CGRP therapies were a major step forward in the treatment of migraine, but most patients are still not adequately controlled,” said Anurag Agarwal, Ph.D., co-founder and chief executive officer of Vedana. “We are now focused on what comes next — targeting biology beyond CGRP, like PACAP and combinations thereof, to deliver on our vision of migraine freedom for all patients.” Approval of multiple CGRP medicines marked the launch of the first generation of specialized therapies for migraine patients. However, two-thirds of the patients are still unable to gain optimal control of their migraine. PACAP, like CGRP, plays a critical role in migraine physiology and is emerging as a complementary approach to treat patients. Based on such clinically validated biology, Vedana has built a portfolio of internally discovered subcutaneously delivered long-acting antibodies. The company’s lead program is the next-generation anti-PACAP antibody, and its second program targets both PACAP and CGRP. While targeting PACAP alone provides a novel approach beyond currently approved drugs, Vedana’s bispecific antibody targeting both PACAP and CGRP could potentially deliver additional efficacy for patients who do not achieve relief with monotherapies. Co-founder and chief scientific officer Leon Garcia, Ph.D., added, “Vedana was founded by a team that has spent years developing antibody therapies against CGRP and PACAP, giving us deep insight into both the promise and the limitations of existing approaches. Drawing on that experience, we designed the next-generation of highly potent long half-life antibodies, targeting self-injecting options for patients in the convenience of their home.” “Vedana’s team has an unparalleled track record and has executed efficiently in generating multiple molecules with best-in-class potential,” said Mira Chaurushiya, Ph.D., managing director at Westlake BioPartners. “As the migraine market continues to evolve, Vedana’s leadership is well positioned to identify and address patient needs.” “The Vedana team represents the deepest concentration of migraine expertise we have seen. Importantly, they bring together the lived experiences from multiple migraine companies and medicines in large and small biotech. They are focused entirely on what the next generation of medicines needs to deliver for patients. We are proud to back them,” said Julie Grant, general partner at Canaan Partners. Built by the Team Behind Modern Migraine Therapeutics Vedana was built by the world’s leading migraine experts and industry leaders with decades of experience across migraine biology, antibody engineering, clinical development, and commercialization. Vedana’s executive leadership team includes: Anurag Agarwal, Ph.D., co-founder and chief executive officer (CEO) – Brings a decade of experience in investing in early stage life science companies as a venture capitalist at Osage University Partners where he led multiple company creation initiatives. Leon Garcia, Ph.D., co-founder and chief scientific officer – Led the discovery and development of both anti-calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) antibodies at Alder BioPharmaceuticals (acquired by Lundbeck), with more than 30 years of experience in antibody development from discovery through late-stage clinical trials. Ernesto Aycardi, M.D., chief medical officer (CMO) – Brings global experience across all phases of drug development, with deep expertise in neurology, having managed the pivotal and post-marketing studies for AJOVY® (fremanezumab-vfrm). In addition, Vedana is supported by internationally renowned leaders in the migraine field, including: Rob Lenz, M.D., Ph.D., executive chair of Vedana’s board of directors -- Former head of global development at Amgen, where he led the development of Aimovig® (erenumab-aooe). Marcelo Bigal, M.D., Ph.D. , member of Vedana’s board of directors -- Former CMO of Labrys, and head of development at Teva, where he led the development of AJOVY® (fremanezumab-vfrm). Steven James – Former CEO of Labrys Biologics (acquired by Teva for AJOVY®), KAI Pharmaceuticals (acquired by Amgen), and Pionyr Immunotherapeutics (acquired by Gilead Sciences). Messoud Ashina, M.D., Ph.D. – Director of the Migraine Unit at the University of Copenhagen and a leading authority in migraine research. David Dodick, M.D. – Chief science and medical officer at Atria and a globally recognized migraine expert. Andy Russo, Ph.D. – Professor of neurology at the University of Iowa and leading preclinical researcher in CGRP and PACAP biology. Frank Porreca, Ph.D. – Associate department head of pharmacology at the University of Arizona and prominent researcher in preclinical models of pain. About Vedana Therapeutics Vedana Therapeutics is a biotechnology company developing next-generation, preventive therapies for migraine by leveraging pituitary adenylate cyclase-activating polypeptide (PACAP) biology, and highly selective combinatorial targeting of clinically validated pathways. Vedana is led by a team of world-renowned experts in migraine drug development and is advancing a portfolio of antibody-based therapies designed to address the significant unmet need in migraine treatment. Visit for more information. Contacts Media Contact Greig Communications, Inc. Kathy Vincent kathy@greigcommunications.com

Acquisition

100 Deals associated with Erenumab (Genetical Recombination)

External Link

KEGG	Wiki	ATC	Drug Bank
D10928	Erenumab (Genetical Recombination)	N02CD01	DB14039

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Migraine Disorders	United States	Amgen, Inc.	17 May 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Trigeminal Nerve Diseases	Phase 2	United States	Amgen, Inc.	31 May 2022
Trigeminal Nerve Injuries	Phase 2	United States	Amgen, Inc.	31 May 2022
Temporomandibular Joint Disorders	Phase 2	United States	Amgen, Inc.	15 Nov 2021
Flushing	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	09 Jun 2020
Rosacea	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	09 Jun 2020
Neuralgia	Phase 2	Denmark	Novartis AG	09 Apr 2019
Trigeminal Neuralgia	Phase 2	Denmark	Novartis AG	09 Apr 2019
Headache	Phase 2	Denmark	Amgen, Inc.	05 Apr 2019
Headache	Phase 2	Denmark	Novartis AG	05 Apr 2019
Post-Concussion Syndrome	Phase 2	Denmark	Amgen, Inc.	05 Apr 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03867201 (DRAGON, Pubmed \| J Headache Pain)	Phase 3	Migraine Disorders	226	Erenumab 70 mg (Chronic Migraine)	dobrahbwgy(puenfuuwrw) = fqznuwnybn elnhbascks (zbhsuepols ) View more	Positive	17 Jun 2026
NCT03333109 (EMPOwER, Pubmed \| Neurol Clin Pract)	Phase 3	Migraine Disorders	900	Erenumab 140 mg	yuxhirxvay(jetnpiyjky) = jmcceryciz gytstmyoti (uofvjnxmfo ) View more	Positive	01 Apr 2026
				Erenumab 70 mg	yuxhirxvay(jetnpiyjky) = ivlfyycpoj gytstmyoti (uofvjnxmfo ) View more
NCT04603976 (REFORM, Pubmed \| Eur J Neurol)	Phase 4	Migraine Disorders	582	Erenumab 140 mg	fbrjohlcka(rwvtmjdyct) = For HIT-6, optimal thresholds included an 8-point reduction (53% sensitivity, 84% specificity) or a 12% relative reduction (54% sensitivity, 84% specificity). hvuohatjit (clqavlbuon ) View more	Negative	01 Apr 2026
NCT04252742 (EMBRACE, Pubmed \| Headache)	Phase 4	-	510	Erenumab 140 mg	mffwebtffz(eelyzazyxv) = Compared with placebo, erenumab significantly reduced migraine functional impact as assessed by the four domains of the Migraine Functional Impact Questionnaire, with a least squares mean (95% CI) difference of −7.36 (−10.80, −3.92) for physical functioning, −7.10 (−10.34, −3.87) for usual activities, −6.82 (−10.37, −3.27) for social functioning, and − 7.05 (−10.76, −3.34) for emotional functioning ( p < 0.001 for all domains). yqizbqgukq (uklulpfqkv )	Positive	01 Mar 2026
				Placebo
NCT04098250 (CTgov)	Phase 2	Post-Traumatic Headache	6	Erenumab (Erenumab)	jnqnanafxa(vlispxixha) = vklaesvzls hxrmafhwks (zsxqpgoyer, 2.8) View more	-	23 Oct 2025
				Placebo (Placebo)	jnqnanafxa(vlispxixha) = fjxprjsxho hxrmafhwks (zsxqpgoyer, 6.0) View more
NCT04884763 (CTgov)	Phase 2	Temporomandibular Joint Disorders	30	Erenumab-aooe (Arm A)	apxprhruoz(dfvjckwcwf) = xfiudsjyjq gglgqadpbs (uzmeobmdwt, gxksqiszsj - wcysudqnmu) View more	-	19 Aug 2025
				Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments (Arm B)	apxprhruoz(dfvjckwcwf) = whmeqtcdqd gglgqadpbs (uzmeobmdwt, owlphgsuzb - jygvcgsbbs) View more
NCT03971071 (Pubmed \| Eur J Neurol)	Phase 4	Headache Disorders, Secondary	552	Erenumab 70 mg	btnqpjnaod(bnxixazpkm) = No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]) gaiglybbub (jhyoabyhfs )	Positive	01 Aug 2025
				Erenumab 140 mg
NCT04970355 (CHERUB01, Pubmed \| JAMA Netw Open)	Phase 2	Cluster Headache CGRP	81	Erenumab	kmabvognop(uqfvpoafyv) = adtsbftvgj hukprnfalw (jvrjbnwxbi )	Negative	17 Jun 2025
				Placebo	kmabvognop(uqfvpoafyv) = czixdmpmsy hukprnfalw (jvrjbnwxbi )
NCT04674020 \| NCT04603976 (REFORM study, Pubmed \| J Headache Pain)	Phase 4	Migraine Disorders soluble urokinase-plasminogen activator receptor (suPAR)	623	Erenumab 140 mg	ytrvdnmdkm(mxzkwkmshv): P-Value = 0.005	Negative	24 Apr 2025
				erenumab (Healthy Controls)
NCT04084314 (APOLLON, Pubmed \| J Headache Pain) Manual	Phase 4	Migraine Disorders	701	Erenumab 70 mg	cwuqteorqb(xwexoukurk) = 4.1% of total cohort discontinued erenumab treatment during open-label treatment phase. Out of these, 65.5% (N = 19) were considered treatment-related. fkepltuquw (yyekxkebhq )	Positive	25 Sep 2024
				Erenumab 140 mg

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis